Serabelisib
- Generic Name
- Serabelisib
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17N5O3
- CAS Number
- 1268454-23-4
- Unique Ingredient Identifier
- 43J9Q56T3W
- Background
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Faeth Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT06463028
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Florida Cancer Specialists, North, Saint Petersburg, Florida, United States
Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations
- Conditions
- Advanced Solid TumorPIK3CA MutationPTEN Loss of Function Mutation
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Faeth Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT05300048
- Locations
- 🇺🇸
New Jersey Cancer Care, PA, Belleville, New Jersey, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Northwell Health, Lake Success, New York, United States
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
- Conditions
- Endometrial CancerLung CancerColo-rectal CancerBreast CancerHead and Neck Cancer
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Petra Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT04073680
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Avera McKennan Hospital & University Health Center
- Target Recruit Count
- 19
- Registration Number
- NCT03154294
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
- Conditions
- Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02724020
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
🇫🇷Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
- Conditions
- Endometrial Neoplasms
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT02725268
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States
🇺🇸University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
- Conditions
- Neoplasm, Advanced or Metastatic
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02625259
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
- Conditions
- Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02551055
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02393209
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
- Conditions
- Advanced Nonhematologic Malignancies
- Interventions
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01899053
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.